Conclusions: As compared with other PPIs, esomeprazole confers a statistically significant improvement, yet, clinically, only a modest overall benefit in 8-week healing and symptom relief in all-comers with EE
Upsides
Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat symptoms of gastroesophageal reflux disease (GERD) and conditions
137 patients, pooled healing rate = 84
Esomeprazole, as the isomer of omeprazole, has been developed and marketed with less adverse events compared with omeprazole (19, 20)
Omeprazole 20 mg and rabeprazole 20 mg represented the “low effective and withdrawal rate” cluster
They are: lansoprazole; omeprazole; esomeprazole; pantoprazole; Like rabeprazole, these medicines are proton pump inhibitors (PPIs)
5 days) and patient’s global evaluation at 4 weeks (96% on rabeprazole reported symptoms
This study compared the effect of two PPIs on early symptom relief in Japanese patients with reflux esophagitis, classified by the CYP2C19 phenotype
10,14 This could be due to the larger acid-neutralizing capacity (mEq HCl/g) of CaCO 3, which is nearly double that of
Rabeprazole is not for immediate relief of heartburn
pylori eradication treatments over time makes the search for better regimens and adjuvant medications a priority
R) were orally administered daily for 7 days
In our main outcome, we provided more precise ranking results: esomeprazole at 40 mg per day from the PPI family ranked first, followed by rabeprazole at 40–50 mg per day and pantoprazole at 80 This specific enantiomer has an advantage over metabolism
in a Kenyan population employing same Background: The objective of this study was to compare the efficacy of pantoprazole and esomeprazole to heal and relief from erosive esophagitis (EE) disease related symptoms
It relieves symptoms such as heartburn, difficulty swallowing, and persistent cough